McGill IBD logo
Donate

MUHC Publications: November 2025 – November 2026

MUHC Activities

  1. Dupilumab Improves Esophageal Distensibility in EoE: 24-Week Results From the REMODEL Randomized Trial. Dellon ES, Carlson DA, Greuter T, Collins MH, Lankarani A, Talreja N, Ravi K, Simões Neto J, Afif W, Gonsalves NP, Lynch KL, Zaghloul S, Cunoosamy D, Durrani SR, Zhang M, Raphael BP, Angello JT, Radwan A, Almansa C, Biedermann L.Am J Gastroenterol. 2026 Oct 12. doi: 10.14309/ajg.0000000000004227. Online ahead of print.PMID: 42861971
  2. The Association of Faecal Calprotectin Measurements With Endo-Histological Remission in Ulcerative Colitis: A Pooled Analysis. Dubé LR, Sorin M, Allez M, Afif W, Bitton A, Lakatos PL, Wild G, Magro F, Patel A, Guardiola J, Bessissow T.Aliment Pharmacol Ther. 2026 Sep;64(5):615-624. doi: 10.1111/apt.70735. Epub 2026 Jun 2.PMID: 42227157 Free PMC article.
  3. Five-year efficacy and safety of guselkumab for moderately to severely active Crohn’s disease: Results from the phase 2 GALAXI 1 trial. Afzali A, Danese S, Panaccione R, Rubin DT, Sands BE, Reinisch W, Panés J, Van Rampelbergh R, Terry NA, Salese L, Vetter ML, Yee J, Corbett C, van Duijnhoven W, Hisamatsu T, Andrews JM, D’Haens GR; GALAXI 1 investigators (Afif W).Inflamm Bowel Dis. 2026 Sep 1;32(9):1669-1682. doi: 10.1093/ibd/izag055.PMID: 42065683 Free PMC article. Clinical Trial.
  4. Efficacy and Safety of Dupilumab in Eosinophilic Esophagitis: A Systematic Review and Meta-Analysis. Khalaf R, Ton That A, Tardio N, Afif W, Schneider R, Ben-Shoshan M.Int Arch Allergy Immunol. 2026 Jul 15:1-7. doi: 10.1159/000553602. Online ahead of print.PMID: 42455743 Free PMC article.
  5. Proactive Fecal Calprotectin Home Monitoring in Ulcerative Colitis: Results of a Prospective Randomized Controlled Trial. Rosenfeld G, Narula N, Leung Y, Afif W, Williams AJ, Huang V, Singh H, McCurdy JD, Jairath V, Lam M, Loomes DE, Zezos P, Stewart M, Ma C, Ropeleski M, Ancheta-Schmit M, Tavakoli P, Bone JN, Lewis JD, Colombel JF, Bressler B.Gastroenterology. 2026 Jun 23:S0016-5085(26)06980-5. doi: 10.1053/j.gastro.2026.06.006. Online ahead of print.PMID: 42336164 Free article.
  6. An observational cohort study evaluating adalimumab concentrations for predicting non-recapture of biochemical response after dose escalation in patients with Crohn’s disease experiencing secondary loss of response. De Marco D, McHugh K, Plamondon S, Rioux LC, Steinhart AH, Horvat M, Afif W.J Can Assoc Gastroenterol. 2026 Feb 18;9(3):153-161. doi: 10.1093/jcag/gwag002. eCollection 2026 Jun.PMID: 42244850 Free PMC article.
  7. Evaluation of Injection Site Pain and Adherence in Patients Transitioning from a High to Low Volume Adalimumab Formulation (AVT02, Simlandi®) Across Multiple Indications (EASE PAIN). Shahrokh DK, Vender RB, Lynde CW, Rao J, Afif W, Steinhart AH, Narula N, Sutton E, Thorne C, Bessette L.Rheumatol Ther. 2026 Jun;13(3):745-765. doi: 10.1007/s40744-026-00846-1. Epub 2026 Apr 10.PMID: 41963765 Free PMC article.
  8. Eosinophilic Esophagitis following Oral Immunotherapy: A Systematic Review and Meta-Analysis. Khalaf R, Fields M, Fields E, Tardio N, Afif W, Schneider R, Ben-Shoshan M.Int Arch Allergy Immunol. 2026 May 8:1-8. doi: 10.1159/000552457. Online ahead of print.PMID: 42102009 Free PMC article.
  9. Efficacy and Safety of Guselkumab for Ulcerative Colitis Through Week 92 of the QUASAR Long-Term Extension Study. Lichtenstein GR, Allegretti JR, Rubin DT, Magro F, Bressler B, Panés J, Afif W, Samaan MA, Ye BD, Yarandi S, Germinaro M, Shipitofsky N, Miao Y, Zhang H, Dignass A, Sands BE, Hisamatsu T, Peyrin-Biroulet L.Am J Gastroenterol. 2026 May 1. doi: 10.14309/ajg.0000000000004041. Online ahead of print.PMID: 42065421
  10. Personalized infliximab rescue therapy to maximize colectomy-free survival in patients with acute severe ulcerative colitis. Niyigena E, Hoffert Y, Afif W, Pedicelli A, Roblin X, Hanžel J, Papamichael K, Kobayashi T, Elens L, Wang Z, Ferrante M, Verstockt B, Vermeire S, Vande Casteele N, Battat R, Dreesen E.J Crohns Colitis. 2026 Mar 10;20(3):jjag029. doi: 10.1093/ecco-jcc/jjag029.PMID: 41873130
  11. Comparable remission and health care use in real-world inflammatory bowel disease patients initiating originator biologics vs Moura CS, Etingin A, Lukusa L, Singh H, Narula N, Targownik LE, Leung Y, Zezos P, Polewiczowska-Nowak B, Afif W, Bernatsky S.World J Gastroenterol. 2026 Mar 7;32(9):114580. doi: 10.3748/wjg.v32.i9.114580.PMID: 41810446 Free PMC article.
  12. Drug Discontinuation and Persistent Symptoms Among Initiators of Bio-Originator and Biosimilar anti-Tumor Necrosis Factor Drugs in Inflammatory Bowel Disease: Real-World Contemporary Data From the CAnadian Network for Advanced Interdisciplinary Methods/CIRC Registry. Oketola B, Bernatsky S, Lukusa L, Moura CS, Neville A, Leung Y, Narula N, Afif W, Birck MG, Zezos P, Singh H; Canadian IBD Research Consortium.Gastro Hep Adv. 2025 Sep 30;5(2):100821. doi: 10.1016/j.gastha.2025.100821. eCollection 2026.PMID: 41362822 Free PMC article.
  13. Recommendations for the diagnosis and management of eosinophilic esophagitis in adults and children in Canada: a Delphi consensus project. Avinashi V, Gupta M, Payne BA, Amhaz H, Temirova AT, Afif W, Ashok D, Barkey J, Burnett D, Bush JW, Cameron S, Carr S, El Demellawy D, Erdle S, Huynh HQ, Griffin J, Grover SC, Grzywacz K, Jeimy S, Ko HH, Lacuesta G, Marcon M, Mayrand S, Petropolis H, Rodrigues D, Sherlock M, Song C, Tardio N, Vander Leek TK, Vurzinger M, Williams B, Xenodemetroupolous T, Ma C, Chan ES.J Can Assoc Gastroenterol. 2025 Nov 6;8(6):207-227. doi: 10.1093/jcag/gwaf022. eCollection 2025 Dec.PMID: 41393983 Free PMC article.
  14. Recommendations for the diagnosis and management of eosinophilic esophagitis in adults and children in Canada: a Delphi consensus project. Avinashi V, Gupta M, Payne BA, Amhaz H, Temirova AT, Afif W, Ashok D, Barkey J, Burnett D, Bush JW, Cameron S, Carr S, Demellawy DE, Erdle S, Huynh HQ, Griffin J, Grover SC, Grzywacz K, Jeimy S, Ko HH, Lacuesta G, Marcon M, Mayrand S, Petropolis H, Rodrigues D, Sherlock M, Song C, Tardio N, Vander Leek TK, Vurzinger M, Williams BA, Xenodemetropoulos T, Ma C, Chan ES.Allergy Asthma Clin Immunol. 2025 Nov 7;21(1):47. doi: 10.1186/s13223-025-00993-0.PMID: 41204373 Free PMC article.
  15. Defining Fecal Calprotectin Cutoffs That Predict Endoscopic and Histologic Remission in Patients With Ulcerative Colitis. Drügg Hahn G, Lakatos PL, Maedler-Kron C, Marcus V, Afif W, Wild G, Bitton A, Flores C, de Magalhães Francesconi CF, Bessissow T.Inflamm Bowel Dis. 2025 Nov 1;31(11):2977-2985. doi: 10.1093/ibd/izaf008.PMID: 40973642 Free article.
  16. Personalizing IL-23 Inhibitor Therapy in IBD: Current Evidence and Future Directions in Therapeutic Drug Monitoring and Dose Optimization. Pedicelli A, Bessissow T, Afif W.J Clin Med. 2025 Oct 22;14(21):7471. doi: 10.3390/jcm14217471.
  17. A modified synchrotron X-ray phase-contrast micro-CT workflow for non-destructive 3D imaging of intestinal biopsies. Ngew E, Stobbs JA, Bessissow T, George S.Talanta. 2026 Nov 1;309:130019. doi: 10.1016/j.talanta.2026.130019. Epub 2026 May 18.PMID: 42161198 Free article.
  18. A Hidden Stalk: The Giant Pedunculated Brunner Gland Hamartoma Presenting as a Duodenal Subepithelial Mass. Al Alawi S, Bessissow T, Marcus V, Al Nasir M, Ouakaa A, Chen YI.ACG Case Rep J. 2026 Sep 22;13(9):e02323. doi: 10.14309/crj.0000000000002323. eCollection 2026 Sep.PMID: 42775346 Free PMC article. No abstract available.
  19. Rectal Metastasis from Breast Cancer: A Case Report and Review of Literature. Coutu FA, Hagh-Doust H, Maedler-Kron CR, Asselah J, Bessissow T.Case Rep Gastroenterol. 2026 Jul 15;20(1):311-328. doi: 10.1159/000550604. eCollection 2026 Jan-Dec.PMID: 42609907 Free PMC article.
  20. Practices and perceptions of advanced endoscopic imaging techniques for colorectal neoplasia detection in patients with inflammatory bowel disease: report of a survey among Canadian inflammatory bowel disease specialists. van Lierop LMA, Dang R, Bessissow T, Narula N, Ramsay T, Greenstreet P, Hoentjen F, Murthy SK.IGIE. 2026 Feb 14;5(2):173-181.e6. doi: 10.1016/j.igie.2026.02.006. eCollection 2026 Jun.PMID: 42394880 Free PMC article.
  21. Successful Treatment of Refractory Pruritus in Primary Sclerosing Cholangitis with Upadacitinib: A Case Report. Nadeem H, Lakatos PL, Hagh-Doust H, Wyse JM, Nadeem H, Bessissow T.Case Rep Gastroenterol. 2026 Apr 27;20(1):157-166. doi: 10.1159/000552074. eCollection 2026 Jan-Dec.PMID: 42368781 Free PMC article.
  22. Rare Rectal Involvement of Metastatic Appendiceal Adenocarcinoma Mimicking Primary Rectal Cancer. Aboulhamid N, Zoughlami A, Evaristo G, Bessissow T.ACG Case Rep J. 2026 Mar 23;13(3):e02045. doi: 10.14309/crj.0000000000002045. eCollection 2026 Mar.PMID: 41878149 Free PMC article.
  23. Communicating Needs and Features of IBD Experiences study: Canadian individuals and healthcare professional perceptions of the experience and impact of symptoms of moderate-to-severe ulcerative colitis and Crohn’s disease. Jairath V, Bessissow T, Glass J, Braun M, Gibble TH, Movsessian T, Atkinson C, Ellis H, Dewar T, Panaccione R.J Can Assoc Gastroenterol. 2026 Jan 14;9(1):38-48. doi: 10.1093/jcag/gwaf036. eCollection 2026 Feb.PMID: 41669714 Free PMC article.
  24. Closing the Middle East and north Africa representation gap in clinical trials in inflammatory bowel disease. Shebab M, Al-Hindawi A, Goodwin SW, Yuan Y, Bessissow T, Peyrin-Biroulet L, Jairath V.Lancet Gastroenterol Hepatol. 2026 Feb;11(2):89-91. doi: 10.1016/S2468-1253(25)00346-2. Epub 2025 Nov 25.PMID: 41314228 No abstract available.
  25. Effectiveness and Safety of Advanced Combination Treatment in Patients With Refractory Inflammatory Bowel Disease or Concomitant Immune-Mediated Disease or Extraintestinal Manifestations: A Multicenter Canadian Study. Solitano V, Ogunsakin RE, Yuan Y, Bernstein CN, Bessissow T, Bressler B, Hoentjen F, van Lierop L, Leung Y, Ma C, Marshall JK, Narula N, Alahmari M, Mccurdy JD, Murthy S, Panaccione R, Rosenfeld G, Milgrom R, Silverberg M, Jairath V.Am J Gastroenterol. 2026 Feb 1;121(2):410-423. doi: 10.14309/ajg.0000000000003573. Epub 2025 Jun 5.PMID: 40471825
  26. Comparative Efficacy of Medical Therapies in Reducing the Risk of Postoperative Recurrence in Crohn’s Disease: A Systematic Review and Network Meta-Analysis. Shehab M, Alrashed O, Alrashed F, Alyousefi R, Zoughlami A, Lakatos P, Allez M, Jairath V, Regueiro M, Bessissow T.Inflamm Bowel Dis. 2026 Jan 1;32(1):25-38. doi: 10.1093/ibd/izaf186.PMID: 40973202 Free article.
  27. Fecal microbiota transplantation to reduce immune activation in ART-treated people with HIV with low CD4/CD8 ratio: protocol for the single-blind, randomized, placebo-controlled Gutsy study (CIHR/CTN PT038). Isnard S, Berini CA, Parvathy SN, Feng H, Aiyana O, Royston L, Mabanga T, Lakatos PL, Bessissow T, Klein MB, Lebouché B, Costiniuk CT, Routy B, Silverman MS, Routy JP.Trials. 2025 Dec 13;27(1):52. doi: 10.1186/s13063-025-09345-0.PMID: 41390455 Free PMC article.
  28. Combination of underwater and traction-assisted endoscopic submucosal dissection: the perfect wedding for a challenging case. Al Alawi S, Bessissow T, Tsoukas S, Ureña Campos R, Lu Y, Chen YI, Jacques J.Endoscopy. 2025 Dec;57(S 01):E1233-E1234. doi: 10.1055/a-2723-1869. Epub 2025 Nov 5.PMID: 41192446 Free PMC article. No abstract available.
  29. Editorial: The Devil Is in the Detail-Interpreting the Findings of Network Meta-Analyses. Authors’ Reply. Shehab M, Hassan A, Bessissow T.Aliment Pharmacol Ther. 2025 Dec;62(11-12):1224-1225. doi: 10.1111/apt.70342. Epub 2025 Sep 5.PMID: 40913345 No abstract available.
  30. Hemostatic powder’s battle against a spurting bleeding ulcer: can it win? Al Alawi S, Bessissow T, Fallone CA, Jacques J, Barkun A.Endoscopy. 2025 Dec;57(S 01):E676-E677. doi: 10.1055/a-2610-3096. Epub 2025 Jun 26.PMID: 40570926 Free PMC article. Clinical Trial. No abstract available.
  31. Pharmacological management of upper gastrointestinal Crohn’s disease: a systematic review. Chatto M, Alaskar D, Ma C, Yuan Y, Vuyyuru SK, Bessissow T, Narula N, Danese S, Peyrin-Biroulet L, Singh S, Jairath V, Sedano R.J Crohns Colitis. 2025 Nov 8;19(10):jjaf187. doi: 10.1093/ecco-jcc/jjaf187.PMID: 41148060 Free PMC article.
  32. Effects of Ultra-Processed Foods and Food Additives on Disease Activity in Adults with Inflammatory Bowel Disease: A Scoping Review. Soublette Figuera A, Alessa S, Brien C, Hendrickson M, Kasvis P, Bessissow T.J Clin Med. 2025 Nov 3;14(21):7798. doi: 10.3390/jcm14217798.PMID: 41227194 Free PMC article.
  33. Exploration of international differences in preoperative characteristics, indications, postoperative management and endoscopic recurrence rates in patients with Crohn’s disease following ileocolic (re-)resection: first outcomes from the IMPACT consortium. Bak MTJ, Hammoudi N, Lee SH, Maggiori L, van Ruler O, Bezault M, Hernandez-Rocha C, de Vries AC, Silverberg MS, Allez M; IMPACT (International Multidisciplinary Research Collaboration on Postoperative IBD) consortium; on behalf of the Dutch Initiative on Crohn and Colitis and the RAP-CD study group; on behalf of the NIDDK Inflammatory Bowel Disease Genetics Consortium; on behalf of the REMIND study group.J Crohns Colitis. 2026 Oct 9;20(10):jjag137. doi: 10.1093/ecco-jcc/jjag137.PMID: 42918626 Free PMC article.
  34. From preclinical phase of Crohn’s disease to postoperative recurrence: shared mechanisms and potential interventions. Chen R, Turpin W, Allez M, Silverberg MS, Croitoru K, Lee SH.Gut. 2026 Sep 7;75(10):2044-2054. doi: 10.1136/gutjnl-2025-337981.PMID: 42209193 Free PMC article.
  35. Optimizing Endoscopic Assessment of Postoperative Crohn’s Disease: A Scoping Review. Bosch SG, Bak MTJ, Lee SH, Van Ruler O, Maggiori L, Burisch J, Seidelin JB, Ye BD, Park SH, Silverberg MS, Allez M, DeVries AC, Hammoudi N; IMPACT consortium.Dig Endosc. 2026 Sep;38(9):e70286. doi: 10.1111/den.70286.PMID: 42732919 Free PMC article.
  36. IOIBD: the International Organization for the Study of Inflammatory Bowel Disease. Dotan I, Dubinsky MC, Siegel CA, Lindsay J, McGovern D, Allez M, Myrelid P, Lewis J, Sands BE, Peyrin-Biroulet L, Danese S, Ahuja V, Kaplan GG, Konings M, Gearry R, Ng SC, Jairath V, Magro F, Silverberg MS, Turner D, Abreu MT, Hart A, Dignass A, Rubin DT; International Organization for the Study of Inflammatory Bowel Diseases (IOIBD).Ther Adv Gastroenterol. 2026 Aug 2;19:17562848261470923. doi: 10.1177/17562848261470923. eCollection 2026.PMID: 42553409 Free PMC article.
  37. Uncovering the Dynamics of Mucosa-Associated Microbiota in Postoperative Recurrence of Crohn’s Disease. Dubois L, Chaussard A, Seksik P, Nancey S, Nachury M, Treton X, Buisson A, Carbonnel F, Fumery M, Peyrin-Biroulet L, Boureille A, Hébuterne X, Serrero M, Louis E, Blanc P, Brot L, Rolhion N, Vermeire S, Manichanh C, Fossmark R, Bezault M, Uzzan M; REMIND Group; Allez M, Sokol H.Gastroenterology. 2026 Jul;171(1):84-98. doi: 10.1053/j.gastro.2026.01.043. Epub 2026 Feb 24.PMID: 41747778 Free article.
  38. Building a Robust Investigator-Initiated Platform: The I-CARE Experience. Kirchgesner J, Beaugerie L, Baumann C, Baert F, Rahier JF, Bergemalm D, Cañete F, Caron B, Cossignani M, Dias S, Farkas K, Girod P, Goren I, Holvoet T, Krasz S, Kumar A, Rimmer P, Sheridan J, Thut J, Uzzan M, Viazis N, Weimers P, Zagórowicz E, Buisson A, Avedano L, Rousseau H, Peyrin-Biroulet L, Sebastian S; I‐CARE Collaborator Group (Allez M).Clin Pharmacol Ther. 2026 Jun;119(6):1537-1546. doi: 10.1002/cpt.70231. Epub 2026 Feb 15.PMID: 41693257 Free PMC article.
  39. Development and External Validation of a Predictive Model for Postoperative Recurrence of Crohn’s Disease in the Biologic Era. Allez M, Bak MTJ, Brand S, Diebakate-Scordamaglia L, Capelle E, Seksik P, Nancey S, Gornet JM, Buisson A, Carbonnel F, Peyrin-Biroulet L, Louis E, Hébuterne X, Serrero M, Bourreille A, Treton X, Wils P, Fumery M, Blanc P, Uzzan M, Sokol H, Barnich N, Kirchgesner J, Colombel JF, Maggiori L, Bezault M, Silverberg MS, De Vries AC, Lambert J, Hammoudi N.Clin Gastroenterol Hepatol. 2026 Mar 27:S1542-3565(26)00220-X. doi: 10.1016/j.cgh.2026.03.015. Online ahead of print.PMID: 41905522 Free article.
  40. Prediction and Prevention of Inflammatory Bowel Disease: A Call to Action. Lee SH, Lopes EW, Khalili H, Croitoru K, Colombel JF, Peter I; 2025 PROMISE Workshop participants (Allez M). Gastroenterology. 2026 Feb;170(2):233-239. doi: 10.1053/j.gastro.2025.09.042. Epub 2025 Dec 18.PMID: 41410638 Free PMC article. No abstract available.
  41. DENetwork unveils non-differentially expressed genes with functional relevance across conditions through information flow perturbation. Zhao B, Su TY, Wang J, Islam QS, Song K, Huang SK, Allez M, Fonseca GJ, Baglole CJ, Ding J.Nucleic Acids Res. 2025 Nov 26;53(22):gkaf1350. doi: 10.1093/nar/gkaf1350.PMID: 41404797 Free PMC article.
  42. β-Glucan and Inulin Estimated Intake Are Associated With Reduced Risk of Crohn’s Disease, Improved Gut Barrier and Systemic Inflammation Markers, and Multi-Omic Signatures in a High-Risk Cohort. Xue M, McShane C, Kim J, Khorasaniha R, Leibovitzh H, Shao J, Chen R, Jeong S, Madsen KL, Griffiths AM, Walters TD, Steinhart AH, Dieleman LA, Huynh HQ, Panaccione R, Aumais GL, Bitton A, Mack D, Jacobson K, Bressler B, Marshall JK, Moayyedi P, Plotkin L, Dotan I, Bernstein CN, El-Matary W, Hyams JS, Otley A, Lee SH, Turner D, Armstrong H, Croitoru K; CCC-GEM Consortium; Turpin W.Gastroenterology. 2026 Oct;171(4):641-655. doi: 10.1053/j.gastro.2026.05.006. Epub 2026 May 28.PMID: 42214560
  43. Childhood exposure to a sibling with Crohn’s disease alters gut microbiome and Crohn’s disease susceptibility. Chen R, Kim HJ, Bushra M, Phi Dang C, Li Q, Espin-Garcia O, Huynh HQ, Jacobson K, Bitton A, Panaccione R, Hyams JS, Mack D, Denson L, Otley AR, Marshall JK, Deslandres C, Bernstein CN, Avni-Biron I, Yerushalmi B, Snapper SB, Abreu M, Wrobel I, Aumais G, Moayyedi P, Silverberg MS, Steinhart AH, Dotan I, Griffiths AM, Turpin W, Croitoru K, Lee SH.Gut. 2026 Aug 25:gutjnl-2026-339257. doi: 10.1136/gutjnl-2026-339257. Online ahead of print.PMID: 42642218
  44. Nationalization of clinical care pathways for inflammatory bowel disease management in Canada. Chappell KD, Tausif A, Seow CH, Panaccione R, Lim A, Tersigni C, Nguyen GC, Wang H, Fehr W, Bitton A, McCabe-Woodrow C, Hoentjen F, Nistor I, Siffledeen J, deBruyn J, McCurdy J, Fu N, Narula N, Bollegala N, Fowler S, Murthy S, Shaffer SR, Huang V, Leung Y, Lee K, de Guzman J, Kroeker KI.J Can Assoc Gastroenterol. 2026 May 19;9(4):218-224. doi: 10.1093/jcag/gwaf043. eCollection 2026 Aug.PMID: 42553877 Free PMC article.
  45. Serum thiol redox-related alterations in asymptomatic first-degree relatives are associated with future Crohn’s disease. Mu K, Xue M, Huynh HQ, Griffiths AM, Turner D, Moayyedi P, Steinhart AH, Dieleman LA, Deslandres C, Bitton A, Mack DR, Jacobson K, Cino M, Aumais G, Panaccione R, Bressler B, Lee SH, Turpin W, Croitoru K; Crohn’s and Colitis Canada Genetics Environment Microbial Project Research Consortium.Redox Biol. 2026 Jul;94:104207. doi: 10.1016/j.redox.2026.104207. Epub 2026 May 14.PMID: 42150424 Free PMC article.
  46. Interleukin23 Receptor Genetic Variants Associate With Crohn’s Disease Risk and Microbiome Changes in Healthy First-Degree Relatives. Leibovitzh H, Neustaeter A, Lee SH, Xue M, Espin-Garcia O, Olivera PA, Huynh HQ, Griffiths AM, Turner D, Madsen KL, Silverberg MS, Steinhart AH, Mack DR, Jacobson K, Moayyedi P, Aumais G, Bernstein CN, Marshall JK, Panaccione R, Xu W; CCC GEM Project Research Consortium (Bitton A); Turpin W, Croitoru K.Clin Gastroenterol Hepatol. 2026 May 27:S1542-3565(26)00390-3. doi: 10.1016/j.cgh.2026.05.011. Online ahead of print.PMID: 42208782 Free article.
  47. Patient-reported Symptoms Are Independent of Extent of Disease in Longstanding Ulcerative Colitis: Magic in Imagine. Bernstein CN, Nugent Z, Panaccione R, Marshall DA, Kaplan GG, Vanner S, Dieleman LA, Graff LA, Otley A, Jones J, Buresi M, Murthy S, Borgaonkar M, Bressler B, Bitton A, Croitoru K, Sidani S, Fernandes A, Moayyedi P.J Clin Gastroenterol. 2026 May-Jun 01;60(5):442-448. doi: 10.1097/MCG.0000000000002329. Epub 2026 Jan 23.PMID: 41575877
  48. Postoperative Ileum Transcriptomics Implicate Sex-Biased Mechanisms in Crohn’s Disease Recurrence.Gettler K, Nagpal S, Washburn S, Tastad C, Zhang J, Sabic K, Lazarev M, Bitton A, Cohen R, Schwartz MB, Barrie A, Gu P, Fleshner P, Bao M, Hernández-Rocha C, McCauley J, Abreu M, Kugathasan S, McGovern DP, Brant SR, Duerr RH, Silverberg MS, Rioux JD, Gibson G, Cho JH.Gastroenterology. 2026 Mar;170(3):511-522. doi: 10.1053/j.gastro.2025.08.038. Epub 2025 Nov 18.PMID: 41251630 Free PMC article.
  49. Symptoms in Persons With Either Active or Inactive Crohn’s Disease Are Agnostic to Disease Phenotype: The Magic in Imagine Study. Bernstein CN, Nugent Z, Panaccione R, Marshall DA, Kaplan GG, Dieleman LA, Vanner S, Graff LA, Otley A, Jones J, Buresi M, Murthy S, Borgaonkar M, Bressler B, Bitton A, Croitoru K, Sidani S, Fernandes A, Moayyedi P.J Clin Gastroenterol. 2026 Jan 1;60(1):61-67. doi: 10.1097/MCG.0000000000002137.PMID: 39853241
  50. Metabolomics reveal distinct molecular pathways associated with future risk of Crohn’s Disease. Xue M, Lee SH, Shao J, Leibovitzh H, Huynh HQ, Griffiths AM, Turner D, Madsen KL, Moayyedi P, Steinhart AH, Silverberg MS, Deslandres C, Bitton A, Mack DR, Jacobson K, Ropeleski MJ, Cino M, Aumais G, Bernstein CN, Panaccione R, Bressler B, Espin-Garcia O, Xu W, Turpin W, Croitoru K; Crohn’s and Colitis Canada Genetics Environment Microbial Project Research Consortium.Gut Microbes. 2025 Dec;17(1):2546998. doi: 10.1080/19490976.2025.2546998. Epub 2025 Sep 5.PMID: 40910526 Free PMC article.
  51. Forecasting the Incidence and Prevalence of Inflammatory Bowel Disease Across Nine Epidemiologic Stage 3 Regions. Coward S, Brunet-Mas E, Burisch J, Lakatos PL, Loftus EV Jr, Kaplan GG; Global IBD Visualization of Epidemiology Studies in the 21st Century (GIVES-21) Consortia.Gastroenterology. 2026 Jul;171(1):154-157. doi: 10.1053/j.gastro.2026.01.009. Epub 2026 Jan 30.PMID: 41621628 Free article. No abstract available.
  52. Upadacitinib Is Associated With Better Clinical and Biochemical Outcomes Than Tofacitinib in Refractory, Moderate-to-Severe Ulcerative Colitis. Farkas B, Resál T, Lakatos PL, Bessissow T, Limdi JK, Armuzzi A, Bezzio C, Savarino EV, Saibeni S, Michalopoulos G, Attauabi M, Seidelin JB, Fousekis FS, Katsanos K, Bacsur P, Bálint A, Ivány E, Szepes Z, Farkas K, Molnár T.Clin Gastroenterol Hepatol. 2026 Jul;24(7):1950-1959. doi: 10.1016/j.cgh.2025.06.049. Epub 2025 Sep 9.PMID: 40935095
  53. IBD and Immune-Mediated Inflammatory Diseases: What Is the Optimal Management? Alsaeid M, Abu Hawi O, Bessissow T, Lakatos PL.J Clin Med. 2026 Jun 6;15(12):4408. doi: 10.3390/jcm15124408.PMID: 42355576 Free PMC article.
  54. Long-Term Disease Course of Crohn’s Disease in a Prospective European Population-Based Inception Cohort: An Epi-IBD Cohort Study. Wewer MD, Lophaven S, Lakatos PL, Gonczi L, Salupere R, Kievit HAL, Nielsen KR, Midjord J, Domislovic V, Krznarić Ž, Pedersen N, Kjeldsen J, Halfvarson J, Sebastian S, Goldis A, Arebi N, Oksanen P, Neumann A, Andersen V, Katsanos KH, Koukoudis A, Turcan S, Ellul P, Kupcinskas J, Kiudelis G, Fumery M, Kaimakliotis IP, D’Inca R, Lombardini S, Hernandez V, Fernandez A, Langholz E, Munkholm P, Burisch J; Epi-IBD Group.Clin Gastroenterol Hepatol. 2026 Jun;24(6):1675-1687. doi: 10.1016/j.cgh.2025.10.022. Epub 2025 Nov 3.PMID: 41192804 Free article.
  55. Inflammatory bowel disease phenotypes in diverse populations: a global comparative analysis. Bernstein CN, Kaplan GG, Nugent Z, Ahuja V, Ananthakrishnan AN, Banerjee R, Burisch J, Chen Y, Epstein D, Forbes AJ, Gonczi L, Gu Y, Gunawan J, Hang DV, Kaibullayeva J, Kopylov U, Kotze PG, Iade B, Lakatos PL, Limsrivilai J, Liang J, Mak JWY, Ng S, Severs M, Shen J, Sood A, Yamamoto-Furusho JK, Yuan S, Wewer MD, Wu K, Windsor JW, Gearry RB; Globalization Cluster of the International Organization for the Study of IBD.J Crohns Colitis. 2026 May 8;20(5):jjag051. doi: 10.1093/ecco-jcc/jjag051.PMID: 42159039 Free PMC article.
  56. Evaluation of Long-Term Outcomes of Crohn’s Disease Complicated by Intra-Abdominal Abscess: A Retrospective International Cohort Study. Bacsur P, Nemeczek S, Filip R, Fousekis F, Mpakogiannis K, Kagramanova A, Argyriou K, Pastras P, Triantos C, Miheller P, Casanova MJ, Chaparro M, Blesl A, Vieujean S, Iliás Á, Gönczi L, Toruner M, Brinar M, Gatt Y, Gawon-Kiszka M, Tajti J, Lázár G, Resál T, Farkas B, Gálfalvi N, Pápista M, Lakatos PL, Farkas K, Molnár T.J Clin Med. 2026 Apr 3;15(7):2724. doi: 10.3390/jcm15072724.PMID: 41977024 Free PMC article.
  57. Management of Patients with Ulcerative Proctitis: A Global Survey. Caron B, Sequier L, Dignass A, Ghosh S, Hart A, Jairath V, Kobayashi T, Kotze PG, Lakatos PL, Louis E, Magro F, Sebastian S, Solitano V, Sidhu S, Danese S, Peyrin-Biroulet L.Dig Dis Sci. 2026 Apr;71(4):1416-1424. doi: 10.1007/s10620-025-09538-2. Epub 2025 Nov 8.PMID: 41205107 Free article.
  58. International Magnetic Resonance Imaging Consensus for Use in Luminal Crohn’s Disease Trials and Clinical Practice. Caron B, Jairath V, Sands BE, Rubin DT, Allocca M, Laurent V, Novak K, Panaccione R, Bossuyt P, Bruining DH, Dignass A, Dotan I, Fletcher J, Fumery M, Furfaro F, Halfvarson J, Hart A, Kobayashi T, Cleveland NK, Kucharzik T, Laghi A, Lakatos PL, Leong RW, Loftus EV Jr, Louis E, Magro F, Olivera PA, Shaji S, Siegmund B, Vavricka SR, Danese S, Stoker J, Peyrin-Biroulet L.Clin Gastroenterol Hepatol. 2026 Apr;24(4):1130-1140. doi: 10.1016/j.cgh.2025.08.019. Epub 2025 Aug 27.PMID: 40882718 Free article.
  59. Extensive Colonic Pseudopolyposis Leading to Protein-Losing Enteropathy and Severe Hypoalbuminemia With Refractory Ulcerative Colitis. Nadeem H, Alsaeid M, Bitton A, Nadeem H, Lakatos PL.ACG Case Rep J. 2026 Feb 25;13(2):e02011. doi: 10.14309/crj.0000000000002011. eCollection 2026 Feb.PMID: 41756399 Free PMC article.
  60. Do we need to treat dialysis patients differently? Infliximab therapy in a patient with ulcerative colitis on hemodialysis: a case report. Balogh F, Angyal D, Gonczi L, Lontai L, Lakatos PL, Ilias A.J Med Case Rep. 2026 Feb 4;20(1):130. doi: 10.1186/s13256-026-05835-0.PMID: 41639870 Free PMC article.
  61. Clinical Value of Anti-Integrin αvβ6 Antibody Serum-Level Measurement in Inflammatory Bowel Diseases. Angyal D, Balogh F, Gonczi L, Lontai L, Kosa JP, Garam N, Lakatos PL, Ilias A.J Clin Med. 2026 Jan 24;15(3):948. doi: 10.3390/jcm15030948.PMID: 41682629 Free PMC article.
  62. A 3D Alginate-Gelatin Co-Culture Model to Study Epithelial-Stromal Interactions in the Gut. Tselekouni P, Mohseni-Garakani M, Papa S, Kim SY, Avramoglu RK, Wertheimer MR, Ajji A, Lakatos PL, Rosenzweig DH.Gels. 2026 Jan 13;12(1):70. doi: 10.3390/gels12010070.PMID: 41590095 Free PMC article.
  63. Clinical outcomes and drug sustainability after non-medical switch from ustekinumab originator to biosimilars in inflammatory bowel disease. Kritzinger J, Candel I, Kotrri G, Nadeem H, Afif W, Bitton A, Wild G, Bessissow T, Lakatos PL.World J Gastroenterol. 2025 Dec 28;31(48):114355. doi: 10.3748/wjg.v31.i48.114355.PMID: 41480329 Free PMC article.
  64. New-Onset Ulcerative Colitis after Secukinumab Initiation: A Case Report. Hagh-Doust H, Nadeem H, Bessissow T, Lakatos PL.Case Rep Gastroenterol. 2025 Nov 11;19(1):726-730. doi: 10.1159/000548953. eCollection 2025 Jan-Dec.PMID: 41323447 Free PMC article.
  65. Evaluation and Management of Glucocorticoid-Induced Adrenal Insufficiency in IBD: An Expert Opinion. Law CCY, Sheskier R, Viera-Feliciano N, Delgado-Nieves A, Seth S, Hanžel J, Ma C, Colombel JF, Levine AC, Spencer EA; CORE-IBD Collaborators (Allez M, Lakatos PL).Inflamm Bowel Dis. 2025 Nov 1;31(11):3077-3092. doi: 10.1093/ibd/izaf136.PMID: 40587340 Free article.
  66. An International Consensus on Appropriate Management of Corticosteroids in Clinical Trials in Inflammatory Bowel Disease. Hanžel J, Solitano V, Vuyyuru SK, Panaccione R, Sands BE, Peyrin-Biroulet L, Danese S, D’Haens GR, Atreya R, Allez M, Bernstein CN, Bossuyt P, Bressler B, Bryant RV, Cohen BL, Colombel JF, D’Amico F, Dignass A, Dubinsky M, Fleshner P, Gearry RB, Hanauer SB, Hart AL, Kayal M, Kucharzik T, Lakatos PL, Louis E, Magro F, Narula N, Leong RW, Panés J, Raine T, Ran Z, Regueiro MD, Reinisch W, Singh S, Steinhart AH, Travis S, Ungaro RC, van der Woude CJ, Yamamoto T, Ahuja V, Rubin DT, Dulai PS, Cornfield LJ, Hogan M, Sandborn WJ, Feagan BG, Jairath V, Ma C.Gastroenterology. 2025 Nov;169(6):1282-1293. doi: 10.1053/j.gastro.2025.05.015. Epub 2025 May 28.PMID: 40446946 Free PMC article.
  67. Psychometric testing of the ICECAP-A in patients with coeliac disease: a comparative analysis with EQ-5D-5L. Angyal MM, Pangestu S, Lakatos PL, Brodszky V, Rencz F.Health Qual Life Outcomes. 2025 Oct 31;23(1):112. doi: 10.1186/s12955-025-02443-2.PMID: 41174781

Your donations help deliver specialized and quality care to people with inflammatory bowel disease (IBD) in Quebec.

Your generosity benefits the IBD clinics at the Montreal General Hospital, the Montreal Children's Hospital and the Jewish General Hospital.

Donate